Focused On-demand Library for Membrane-bound transcription factor site-2 protease

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

O43462

UPID:

MBTP2_HUMAN

Alternative names:

Endopeptidase S2P; Sterol regulatory element-binding proteins intramembrane protease

Alternative UPACC:

O43462; Q9UM70; Q9UMD3

Background:

Membrane-bound transcription factor site-2 protease, also known as Endopeptidase S2P, plays a pivotal role in intramembrane proteolysis of key regulatory proteins such as ATF6 and SREBP, crucial for lipid metabolism and ER stress response. Its activity is essential for the proteolytic activation of sterol regulatory element-binding proteins, facilitating their nuclear translocation to activate gene transcription.

Therapeutic significance:

The protein's involvement in diseases like IFAP syndrome 1, Olmsted syndrome, Keratosis follicularis spinulosa decalvans, and Osteogenesis imperfecta 19 highlights its clinical relevance. Understanding the role of Membrane-bound transcription factor site-2 protease could open doors to potential therapeutic strategies for these genetic disorders, offering hope for targeted treatments.